Maarten van der Doelen

Chapter 5

Table 3a. Continued.

median OS (months)

n

HR

95% CI

P

Platelet count, continuous

45

13.0

1.00

1.00-1.00

0.21

ANC, continuous

36

11.0

0.98

0.84-1.14

0.78

NLR, continuous

35

11.0

1.08

0.94-1.24

0.30

0.03

Log PSA

44

13.0

1.23

1.03-1.48

<0.01

Log ALP

43

12.2

1.66

1.16-2.35

ALP, dichotomized (U/L) ALP < 115

16

15.7

1.00

0.04

ALP ≥ 115

27

8.6

2.16

1.05-4.44

<0.01

Log LD (U/L)

33

11.0

7.39

2.54-21.54

LD, dichotomized (U/L) LD < 250

20

15.7

1.00

0.01

LD ≥ 250

13

5.9

2.78

1.23-6.30

Albumin (g/L)

33

13.6

0.96

0.87-1.05

0.34

Table 3b. Multivariable analysis of overall survival. n

HR

95% CI

P

Prior Abiraterone or Enzalutamide

32

No

9

1.00

Yes

23

2.38

0.91-6.23

0.08

<0.01

ECOG, categorical

32

ECOG 0

17

1.00

<0.01 <0.01

ECOG 1

9

10.62

3.07-36.73

ECOG 2-3

6

5.67

1.74-18.47

Log LD <0.01 ALP, alkaline phosphatase; ANC, absolute neutrophil count; CI, confidence interval; CRPC, castration resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; GS, Gleason score; Hb, hemoglobin; HR, hazard ratio; LD, lactate dehydrogenase; NLR, neutrophil-to-lymfocyte ratio; NR, not reached; OS, overall survival; PSA, prostate specific antigen; WBC, white blood cell. *Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity. Bold = P < 0.05. 32 7.67 1.75-33.53

144